Skip to main content
Transparency
Twitter
YouTube
Linkedin
cat
esp
eng
ABOUT US
RESEARCH
COVID-19
INNOVATION AND TRANSFER
LEARNING
LIVING LAB HEALTH
NEWS
COLLABORATE
Cerca
who are you?
Who are you?
I'm an
Investigator
I'm
Community
I'm an
Educator
or Student
I'm a
Collaborator
I'm a
Journalist
IrsiCaixa’s scientific activity search engine
Search by
Filter by strategic line
All lines
Immunopathogenesis
Microbiome
Other diseases
Prevention, eradication and functional cure
New treatments and resistance to antiretrovirals
Filter by research group
All the groups
Retrovirology and Clinical Studies (GREC)
Cell Virology and Immunology (VIC)
Microbial Genomics
Virus-Host Interactions (ViHIT)
Host Genetics and Cellular Immunity
HIV and HCV Genetic and Phenotypic Variability
Tissue Virology (VITI)
Viral Immune Evasion and Vaccines (VIRIEVAC)
Neoantigens and Therapeutic Vaccines for Cancer (NeoVaCan)
Pathogen immunity, signaling and therapeutic applications (PISTA)
Translational Research in Immunology and Aging (TRIA)
From Date
Date
To Date
Date
Search
Filter by category
Strategic lines
Research groups
Researchers
Projects
Publications
Clinical research
Events
Publication
SAMHD1 limits HIV-1 antigen presentation by monocyte-derived dendritic cells
Publication
Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis
Publication
Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors
Publication
Functional Analyses Reveal Extensive RRE Plasticity in Primary HIV-1 Sequences Selected under Selective Pressure
Publication
Increased expression of SAMHD1 in a subset of HIV-1 elite controllers
Publication
HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans
Publication
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Publication
Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients
Publication
Transient increment of HTLV-2 proviral load in HIV-1- coinfected patients during treatment intensification with raltegravir
Publication
Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy
« first
‹ previous
…
38
39
40
41
42
43
44
45
46
…
next ›
last »
IrsiCaixa: Aquesta setmana hem tornat a fer un dels tallers sobre el VIH a centres penitenciaris, aquest cop a Lledoners! És un plaer poder debatre i compartir coneixement en aquest programa, que compta amb col·laboració de la @FECYT_Ciencia. + info
IrsiCaixa: "Jo em vacuno pels nostres pacients i per no tornar a viure una situació com aquesta"--️ Bonaventura Clotet, director d'IrsiCaixa. El Dr Clotet, com altres metges, se suma a la iniciativa de @COMBarcelona i explica una de le
IrsiCaixa: -- No us perdeu les respostes de la Dra @BeaMothe, d'IrsiCaixa, als dubtes dels oients d'@elmonarac1 sobre la vacuna! -- Els vacunats poden transmetre el virus? Qui ha passat la COVID-19 s'ha de vacunar? Totes les vacunes van ig
IrsiCaixa: RT @FLSida: --La vacunación frente a la #COVID19 está recomendada para todas las personas que viven con #VIH. Este colectivo se encuentra en…
IrsiCaixa: RT @elmonarac1: -- EN DIRECTE - Resolem els dubtes sobre la vacuna contra el coronavirus amb @BeaMothe, metgessa i investigadora de la Funda…
IrsiCaixa: -- "Desde que se recibe la 2a dosis, se necesitaría una semana aprox. para que el sistema inmune desarrolle una respuesta protectora contra el #SARSCoV2" --️ Jorge Carrillo, investigador principal en #IrsiCaixa, sobre la vacuna co
IrsiCaixa: RT @linformatiu_tve: Què passa si ens contagiem enmig del procés de vacunació? Quan assolirem la immunitat? @marta_sugranes entrevista Jo…
IrsiCaixa: RT @hivandco_2020: Enhorabuena compañer@s del @SaludISCIII @ibis_sevilla @IrsiCaixa al reconocimiento de la revista Science por la publicac…
IrsiCaixa: RT @FAQSTV3: "La vacuna anirà bé però d'aquí a que generi aquesta immunitat poblacional i puguem mantenir la pandèmia i no hi hagi rebrots…
IrsiCaixa: RT @FAQSTV3: "El 2012, amb l'aparició del MERS, s'hauria d'haver dedicat molts diners a prevenir que aparegués una nova variant pitjor. Cal…
Subscribe to our newsletter
I accept the sending of communications about IrsiCaixa activities, promotions and scientific and educational innovations
*
es
ca
en
Back to Top